Schrodinger Debt to Equity Ratio 2019-2025 | SDGR
Current and historical debt to equity ratio values for Schrodinger (SDGR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Schrodinger debt/equity for the three months ending September 30, 2025 was 0.00.
| Schrodinger Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $0.33B | $0.32B | 1.03 |
| 2025-06-30 | $0.35B | $0.34B | 1.01 |
| 2025-03-31 | $0.37B | $0.37B | 0.99 |
| 2024-12-31 | $0.40B | $0.42B | 0.95 |
| 2024-09-30 | $0.22B | $0.45B | 0.49 |
| 2024-06-30 | $0.21B | $0.47B | 0.45 |
| 2024-03-31 | $0.22B | $0.51B | 0.44 |
| 2023-12-31 | $0.25B | $0.55B | 0.46 |
| 2023-09-30 | $0.23B | $0.56B | 0.41 |
| 2023-06-30 | $0.23B | $0.61B | 0.38 |
| 2023-03-31 | $0.25B | $0.59B | 0.42 |
| 2022-12-31 | $0.24B | $0.45B | 0.54 |
| 2022-09-30 | $0.20B | $0.46B | 0.43 |
| 2022-06-30 | $0.20B | $0.49B | 0.40 |
| 2022-03-31 | $0.19B | $0.53B | 0.36 |
| 2021-12-31 | $0.20B | $0.56B | 0.36 |
| 2021-09-30 | $0.18B | $0.58B | 0.32 |
| 2021-06-30 | $0.11B | $0.61B | 0.18 |
| 2021-03-31 | $0.11B | $0.63B | 0.18 |
| 2020-12-31 | $0.12B | $0.62B | 0.20 |
| 2020-09-30 | $0.05B | $0.63B | 0.08 |
| 2020-06-30 | $0.05B | $0.30B | 0.18 |
| 2020-03-31 | $0.05B | $0.30B | 0.18 |
| 2019-12-31 | $0.06B | $0.10B | 0.58 |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2019-06-30 | $0.00B | $0.00B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.03B | $0.09B | 0.34 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.355B | $0.208B |
| Schr?dinger Inc. provides computational platforms to accelerate drug discovery and materials design deployed by biopharmaceutical and industrial companies, academic institutions and government laboratories. Schr?dinger Inc. is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $39.471B | 45.65 |
| Tempus AI (TEM) | United States | $11.790B | 0.00 |
| Doximity (DOCS) | United States | $8.244B | 33.95 |
| Hims & Hers Health (HIMS) | United States | $7.214B | 58.69 |
| IRhythm Technologies (IRTC) | United States | $5.781B | 0.00 |
| Hinge Health (HNGE) | United States | $3.772B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.859B | 47.30 |
| Privia Health (PRVA) | United States | $2.834B | 177.23 |
| Heartflow (HTFL) | United States | $2.822B | 0.00 |
| 10x Genomics (TXG) | United States | $2.589B | 0.00 |
| Omnicell (OMCL) | United States | $2.277B | 46.55 |
| Azenta (AZTA) | United States | $1.744B | 71.55 |
| Enovis (ENOV) | United States | $1.697B | 8.91 |
| Clover Health Investments (CLOV) | United States | $1.343B | 0.00 |
| Phreesia (PHR) | United States | $1.039B | 0.00 |
| Butterfly Network (BFLY) | United States | $1.021B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.861B | 0.00 |
| Talkspace (TALK) | United States | $0.666B | 134.00 |
| Standard BioTools (LAB) | United States | $0.592B | 0.00 |
| Claritev (CTEV) | United States | $0.478B | 0.00 |
| Evolent Health (EVH) | United States | $0.465B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.384B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.358B | 0.00 |
| Carlsmed (CARL) | United States | $0.337B | 0.00 |
| TruBridge (TBRG) | United States | $0.323B | 14.83 |
| Senseonics Holdings (SENS) | United States | $0.295B | 0.00 |
| CapsoVision (CV) | United States | $0.286B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.262B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.213B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.175B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.174B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.154B | 0.00 |
| CareCloud (CCLD) | United States | $0.129B | 7.09 |
| EUDA Health Holdings (EUDA) | Singapore | $0.087B | 0.00 |
| American Well (AMWL) | United States | $0.085B | 0.00 |
| Pulmonx (LUNG) | United States | $0.084B | 0.00 |
| Outset Medical (OM) | United States | $0.083B | 0.00 |
| HeartBeam (BEAT) | United States | $0.083B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.068B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.068B | 0.00 |
| Precipio (PRPO) | United States | $0.043B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.042B | 0.00 |
| 111 (YI) | China | $0.027B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.023B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| Zhongchao (ZCMD) | China | $0.014B | 0.00 |
| HeartSciences (HSCS) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |